Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2023-06-06 00:00:00 ET · period of report 2023-06-05 · accession 0001140361-23-028539 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-06 | 2023-06-05 | ACRV | Devroe Eric | COO | M - OptEx | $1.04 | +9,225 | 62.9K | +17% | +$9,594 |
| D | 2023-06-06 | 2023-06-05 | ACRV | Devroe Eric | COO | M - OptEx | $0.00 | -9,225 | 96.6K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-05 | M | A | 9,225 | $1.04 | 62,883 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-06-05 | M | D | 9,225 | $0.00 | 96,615 | D | $1.04 · — to 2031-01-13 | 9,225 Common Stock | (F1) Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |